Gene therapy & delivery
The lane
- Status
- Active. Trials are running and the idea is still being tested.
- Verdict
- Dopamine-making gene therapies ended; brain-crossing capsids advance delivery for other branches.
- Family
- Restoration
- Landmarks
- 14 in this lane, 5 more tagged with it. Advanced 7 · Open 4 · Dead end 3
The verdict and status come from the project's branches.yaml and use research wording.
Landmarks in this lane
| AAV-AADC gene therapy | 2004–2019 | Trial in people | Passed this stage | – | – | 19 Oct 2026 | 2 |
| MRI-guided convection-enhanced delivery | 2005–2011 | Research tool | Confirmed and built on | – | – | 19 Oct 2026 | 5 |
| AAV2-GAD sham-controlled Phase 2 | 2008–2025 | Trial in people | Passed this stage | 2 | 45 | 19 Oct 2026 | 4 |
| Intravenous AAV9 reaches the brain | 2009 | Discovery | Confirmed and built on | – | – | 19 Oct 2026 | 0 |
| ProSavin and OXB-102 | 2014–2026 | Trial in people | Did not work | – | – | 19 Oct 2026 | 3 |
| AAV capsids that cross into the brain | 2016–2024 | Research tool | Confirmed and built on | – | – | 20 Oct 2026 | 4 |
| Nusinersen: intrathecal antisense works | 2016–2018 | Trial in people | Passed this stage | 3 | – | 19 Oct 2026 | 4 |
| VY-AADC Phase 1b and RESTORE-1 | 2017–2021 | Trial in people | Did not work | 2 | 14 | 19 Oct 2026 | 7 |
| Focused ultrasound opens the blood-brain barrier | 2018–2022 | Trial in people | Mixed or early results | – | – | 19 Oct 2026 | 3 |
| AAV-PHP.B fails in primates | 2018–2019 | Discovery | Confirmed and built on | – | – | 20 Oct 2026 | 4 |
| Capsids that grip human TfR1 | 2024 | Research tool | Still being studied | – | – | 20 Oct 2026 | 5 |
| CAP-003 intravenous GBA1 gene therapy (Capsida) | 2025–2026 | Trial in people | Did not work | 2 | – | 19 Oct 2026 | 3 |
| VCAP-102 capsid crosses primate blood-brain barrier | 2025 | Research tool | Still being studied | – | – | 20 Oct 2026 | 2 |
| VGN-R08b GBA1 gene therapy (Vitalgen) | 2026–2027 | Trial in people | Mixed or early results | 2 | 17 | 22 Oct 2026 | 5 |
Also tagged with this lane
| GDNF: the growth-factor idea, from infusions to gene therapy | 2003–2026 | Discovery | Still being studied | – | – | 19 Oct 2026 | 4 |
| CERE-120 (AAV2-neurturin) | 2008–2015 | Trial in people | Did not work | 2 | 109 | 19 Oct 2026 | 4 |
| Gene editing of SNCA | 2018–2023 | Lab study (cells or animals) | Still being studied | – | – | 20 Oct 2026 | 3 |
| GBA gene therapy (PR001) | 2020–2026 | Trial in people | Mixed or early results | 1/2 | – | 19 Oct 2026 | 3 |
| REGENERATE-PD AB-1005 | 2024–2028 | Trial in people | Result due Aug 2028 | 2 | 127 | 18 Oct 2026 | 3 |
Links with other lanes
Built on work from
- Lysosome & GBA: 3 links
- Foundations: 1 link
Led to work in
- Growth factors: 3 links
- Synuclein lowering: 3 links
- LRRK2: 1 link